Lexeo TherapeuticsLXEO +1.06%10 OCF Yield % is -26.16 as of Jun. 28, 2026. GuruFocus rates LXEO with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 1,417 Biotechnology companies, Lexeo Therapeutics ranks worse than 73.39% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Lexeo Therapeutics OCF Yield % Related Terms
Lexeo Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Lexeo Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lexeo Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexeo Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Lexeo Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexeo Therapeutics (LXEO) has a OCF Yield % of -26.16 as of Jun. 28, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Lexeo Therapeutics and its competitors. According to the industry distribution chart, Lexeo Therapeutics ranks #1040 out of 1417 companies in the Biotechnology industry, placing it in the top 73.4%.
Is Lexeo Therapeutics' OCF Yield % too high?
Lexeo Therapeutics' current OCF Yield % is -26.16. Based on the distribution chart, Lexeo Therapeutics ranks #1040 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lexeo Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Lexeo Therapeutics' OCF Yield % compare to LYEL and XFOR?
According to the Biotechnology industry distribution chart, Lexeo Therapeutics ranks #1040 out of 1417 companies for OCF Yield %. This places Lexeo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Lexeo Therapeutics and its competitors. Lexeo Therapeutics's current OCF Yield % is -26.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexeo Therapeutics stock overvalued right now?
Lexeo Therapeutics (LXEO) has a current OCF Yield % of -26.16. The current OCF Yield % is -26.16. Lexeo Therapeutics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Lexeo Therapeutics (LXEO), the current OCF Yield % is -26.16 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
10GF Score
Get the complete analysis for LXEO
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LXEO has been successfully added to your 
